Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 15, 2004, Pages 4093-4097

  Reddy, Natala Srinivasa ^a   Mallireddigari, Muralidhar Reddy ^a   Cosenza, Stephen ^a   Gumireddy, Kiranmai ^a   Bell, Stanley C ^a   Reddy, E Premkumar ^a   Reddy, M V Ramana ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coumarins; Jun kinase; Sulfonamides

Indexed keywords

6 CHLOROCOUMARIN 3 (N 4 METHOXY 3 HYDROXYPHENYL)SULFONAMIDE; 6 CHLOROCOUMARIN 3 (N 4 METHOXYPHENYL)SULFONAMIDE; 6 METHOXYCOUMARIN 3 (N 4 BROMOPHENYL)SULFONAMIDE; 6 METHOXYCOUMARIN 3 (N 4 FLUORO 3 AMINOPHENYL)SULFONAMIDE; 8 BROMOCOUMARIN 3 (N 4 BROMOPHENYL)SULFONAMIDE; 8 BROMOCOUMARIN 3 (N 4 METHOXYPHENYL)SULFONAMIDE; 8 CHLOROCOUMARIN 3 (N 4 BROMOPHENYL)SULFONAMIDE; 8 ETHOXYCOUMARIN 3 (N 4 BROMOPHENYL)SULFONAMIDE; 8 ETHOXYCOUMARIN 3 (N 4 FLUORO 3 AMINOPHENYL)SULFONAMIDE; 8 ETHOXYCOUMARIN 3 (N 4 METHOXYPHENYL)SULFONAMIDE; ANTINEOPLASTIC AGENT; COUMARIN DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CATALYST; CHEMICAL REACTION; CONTROLLED STUDY; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MALE; REACTION ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; HUMANS; K562 CELLS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; SULFONAMIDES;

EID: 3042543631     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.05.016     Document Type: Article

References (36)

1. Murray R.D.H., Mendez J., Brown S.A. The Natural Coumarins. 1982;Wiley, New York
2. Williams J.L.R., Specht D.P., Farid S. Polym. Eng. Sci. 23:1983;1022
3. Spino C., Dodier M., Sotheeswaran S. Bioorg. Med. Chem. Lett. 8:1998;3475
4. Madhavan G.R., Balraju V., Mallesham B., Chakrabarti R., Lohray V.B. Bioorg. Med. Chem. Lett. 13:2003;2547
5. Kontogiorgis C., Hadjipavlou-Litina D. J. Enzym. Inhib. Med. Chem. 18:2003;63
6. Hoult J.R.S., Paya M. Gen. Pharmac. 27:1996;713
7. Khan M.S.Y., Sharma P. Indian J. Chem. 32:1993;817
8. Kempen I., Papapostolou D., Thierry N., Pochet L., Counerotte S., Masereel B., Foidart J.M., Reboud-Ravaux M.J., Noel A., Pirotte B. Br. J. Cancer. 88:2003;1111
9. Mora A., Paya M., Rios J.L., Alcaraz M.J. Biochem. Pharmacol. 40:1990;793
10. Reutrakul V., Leewanich P., Tuchinda P., Pohmakotr M., Jaipetch T., Sophasan S., Santisuk T. Planta Med. 69:2003;1048
11. Pochet L., Doucet C., Dive G., Wouters J., Masereel B., Rebound-Ravaux M., Pirotte B. Bioorg. Med. Chem. 8:2000;1489
12. Wouters J., Huygens M., Pochet L., Pirotte B., Durant F., Masereel B. Bioorg. Med. Chem. Lett. 12:2002;1109
13. Mor A., Maillard J., Favreau C., Reboud-Ravaux M. Biochim. Biophys. Acta. 1038:1990;119
14. Doucet C., Pochet L., Thierry N., Pirotte B., Delarge J., Reboud-Ravaux M. J. Med. Chem. 42:1999;4161
15. Egan D., O'Kennedy E., Moran E., Cox D., Prosser E., Thornes R.D. Drug. Metab. Rev. 22:1990;503
16. Nicolaides D.N., Fylaktakidou K.C., Litinas K.E., Hadjipavlou-Litina D. J. Heterocycl. Chem. 33:1996;967
17. Shan B., Medina J.C., Santha E., Frankmoelle W.P., Chou T.C., Learned R.M., Narbut M.R., Stott D., Wu P., Jaen J.C., Rosen T., Timmermans P.B.M.W.M., Beckmann H. Proc. Natl. Acad. Sci. U.S.A. 96:1999;5686
18. Medina J.C., Shan B., Beckmann H., Farrell R.P., Clark D.L., Learned R.M., Roche D., Li A., Baichwal V., Case C., Baeuerle P.A., Rosen T., Jaen J.C. Bioorg. Med. Chem. Lett. 8:1998;2653
19. Rubenstein S.M., Baichwal V., Beckmann H., Clark D.L., Frankmoelle W., Roche D., Santha E., Schwender S., Thoolen M., Ye Q., Jaen J.C. J. Med. Chem. 44:2001;3599
20. Silvio C., Lorenzo P., Alberti B. Gazz. Chim. Ital. 97:1967;1749
21. Mandour A.H., Ahmed Kh.M., Nassar M.I., El-Bazza Z.E. Egyptian J. Pharm. Sci. 36:1995;71
22. Imam I., Aleem El., Abd A.H., Bary El., Abd H., Hossny A.M. Afinidad. 57:2000;217
23. Ismail I.I., El-Hafiz O.M., Nassar M.I. Afinidad. 59:2002;211
24. General experimental procedure for the synthesis of title compounds: Into a R.B. flask were added anilinosulfonyl acetic acid (1 equiv), salicylaldehyde (1 equiv) dissolved in acetic acid (10 mL), and a catalytic amount of benzyl amine (0.001 equiv), and the contents were refluxed for about 8-12 h in an oil bath. After cooling, the precipitated product was filtered and washed with isopropanol and diethyl ether. The pure products obtained were submitted for biological assay
25. General method: To a solution of substituted salicylaldehydes (10 mmol) in warm absolute ethanol (20 mL) was added methyl anilinosulfonyl acetate (11 mmol) and three drops of piperidine. The solution was heated under reflux for 5 min. The crystalline product obtained after cooling was separated by filtration and washed three times with absolute ethanol to obtain a pure coumarin sulfonamide
26. 5) were plated into 6-well dishes and 24 h later each compound was added at five different concentrations over a 2 log dilution (1-100 μM). The total number of viable cells was determined after 96 h of continuous treatment by staining with trypan blue and counting the number of nonstaining cells (viable) remaining in each well using a hemacytometer. The percentage of viable cells remaining was calculated as follows: # viable cells (compound treated)/# viable cells (DMSO treated) * 100. Dose response curves were generated by plotting the percentage of cells at each concentration versus concentration tested
27. Leopold J.S.S. Oncogene. 19:2000;6594
28. Johnson G.L., Lapadat R. Science. 298:2002;1911
29. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Science. 270:1995;1326
30. Posada J., Cooper J.A. Science. 257:1992;1335
31. Davis R.J. Trends Biochem. Sci. 19:1994;470
32. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., Davis R.J. Cell. 76:1994;1025
33. Gille H., Sharrocks A.D., Shaw P.E. Nature. 358:1992;414
34. 32P]ATP (5000 CPM/pmol) and incubating them for 20 min at 30°C using 5 μg GST-c-Jun as substrate. After stopping the reaction with the addition of Laemmli's buffer followed by boiling the samples for 3 min, the phosphorylated GST-c-Jun was separated on 12% SDS-PAGE. The gel was dried, and an autoradiogram was developed
35. Bohmann D., Leppa S. Oncogene. 18:1999;6158
36. Hochedlinger K., Wagner E.F., Sabapathy K. Oncogene. 21:2002;2441